Quantification of the placebo response in ulcerative colitis

Area of Science:

• Gastroenterology
• Clinical Trials
• Inflammatory Bowel Disease

Background:

• A significant placebo effect is consistently observed in ulcerative colitis (UC) treatment trials.
• Understanding the placebo response is crucial for accurately assessing treatment efficacy in UC.

Purpose of the Study:

• To define the placebo response in active ulcerative colitis.
• To identify specific study characteristics that influence the magnitude of the placebo response.

Main Methods:

• A systematic literature search of the MEDLINE database was conducted for placebo-controlled studies in active UC.
• Data extraction and review were performed by multiple investigators to determine placebo remission and benefit rates across clinical, endoscopic, and histological endpoints.
• A synthesis analysis explored the relationship between the placebo response and eight study variables.

Main Results:

• Analysis of 38 studies revealed a clinical remission rate of 9.1% and a benefit rate of 26.7% in the placebo group.
• Similar placebo response rates were observed for endoscopic and histological outcomes.
• The number of study visits significantly influenced the placebo response, with more frequent visits (>3) associated with higher rates of clinical benefit, endoscopic remission, and histological remission (P=0.05, P=0.02, P=0.04, respectively).

Conclusions:

• The placebo remission rate in active UC trials is approximately 10%, with a placebo benefit rate around 30%, consistent across various assessment endpoints.
• Increased frequency of study visits in clinical trials is a significant factor that enhances the placebo response in ulcerative colitis.
• These findings highlight the importance of study design in interpreting placebo effects in UC research.